drugset / Trial / NCT06500299
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
RandomizedParallel-groupQuadruple-blindTreatment
Summary
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.
Timeline
- Start
- 2024-07-15
- Primary completion
- 2024-10-30
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HDM1002 | Unknown | 100 mg | — |
| Subject | HDM1002 | Unknown | 200 mg | — |
| Subject | HDM1002 | Unknown | 400 mg | — |
Indications
No indication recorded.